Biology Reference
In-Depth Information
195. Takekawa M, Saito H. A family of stress-inducible GADD45-like
proteins mediate activation of the stress-responsive MTK1/
MEKK4 MAPKKK. Cell 1998;
95
:521
adjuvant chemotherapy in colorectal cancer? A systematic review
with meta-analysis. Eur J Cancer 2009;
45
:1890
6.
214. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Micro-
satellite instability predicts improved response to adjuvant
therapy with irinotecan, fluorouracil, and leucovorin in stage III
colon cancer: Cancer and Leukemia Group B Protocol 89803. J
Clin Oncol 2009;
27
:1814
e
30.
196. Zhang W, Hoffman B, Liebermann DA. Ectopic expression of
MyD118/Gadd45/CR6 (Gadd45beta/alpha/gamma) sensitizes
neoplastic cells to genotoxic stress-induced apoptosis. Int J Oncol
2001;
18
:749
e
57.
197. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and
JNK/SAPK-dependent apoptosis following inducible expression
of BRCA1. Cell 1999;
97
:575
21.
215. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch
repair as a predictive marker for lack of efficacy of fluorouracil-
based adjuvant
e
e
86.
198. Hildesheim J, Bulavin DV, Anver MR, et al. Gadd45a protects
against UV irradiation-induced skin tumors, and promotes
apoptosis and stress signaling via MAPK and p53. Cancer Res
2002;
62
:7305
e
therapy in colon cancer.
J Clin Oncol
26.
216. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair
proficiency and in vitro response to 5-fluorouracil. Gastroenter-
ology 1999;
117
:123
2010;
28
:3219
e
15.
199. Yang Q, Manicone A, Coursen JD, et al. Identification of a func-
tional domain in a GADD45-mediated G2/M checkpoint. J Biol
Chem 2000;
275
:36892
31.
217. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch
repair system in temozolomide-induced apoptosis. Mol Pharmacol
1998;
54
:334
e
e
8.
200. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant
chemotherapy with 5-fluorouracil in colorectal cancer depends
on the mismatch repair status. Eur J Cancer 2009;
45
:365
41.
218. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch
repair and O6-alkylguanine-DNA alkyltransferase analysis and
response to Temodal in newly diagnosed malignant glioma. J Clin
Oncol 1998;
16
:3851
e
e
73.
201. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of
survival after adjuvant chemotherapy for colon cancer. N Engl J
Med 2001;
344
:1196
e
7.
219. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch
repair protein MSH6 in human glioblastomas is associated with
tumor progression during temozolomide treatment. Clin Cancer
Res 2007;
13
:2038
e
206.
202. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation,
microsatellite instability and adjuvant chemotherapy: impact on
survival of 388 patients with Dukes' C colon carcinoma. Oncology
2000;
58
:52
e
45.
220. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype
and somatic MSH6 mutations in recurrent human malignant
gliomas
e
9.
203. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H.
Microsatellite instability is a favorable prognostic indicator in
patients with colorectal cancer receiving chemotherapy. Gastro-
enterology 2000;
119
:921
e
after
alkylator
chemotherapy.
Cancer
Res
91.
221. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glio-
blastomas during temozolomide therapy and mediate temozo-
lomide resistance. Clin Cancer Res 2009;
15
:4622
2006;
66
:3987
e
8.
204. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil
and survival in patients with microsatellite-unstable colorectal
cancer. Gastroenterology 2004;
126
:394
e
9.
222. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair
deficiency does not mediate clinical resistance to temozolomide
in malignant glioma. Clin Cancer Res 2008;
14
:4859
e
401.
205. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the
prediction of benefit from adjuvant fluorouracil chemotherapy in
colorectal cancer. Gut 2006;
55
:848
e
68.
223. Lebwohl D, Canetta R. Clinical development of platinum
complexes in cancer therapy: an historical perspective and an
update. Eur J Cancer 1998;
34
:1522
e
55.
206. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B.
Association of tumour site and sex with survival benefit from
adjuvant
e
34.
224. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in
platinum drug resistance. Cancer Res 1996;
56
:4881
e
chemotherapy
in
colorectal
cancer.
Lancet
6.
225. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch
repair
e
50.
207. Liang JT, Huang KC, Lai HS, et al. High-frequency microsatellite
instability predicts better chemosensitivity to high-dose 5-
fluorouracil plus leucovorin chemotherapy for stage IV sporadic
colorectal cancer after palliative bowel resection. Int J Cancer
2002;
101
:519
2000;
355
:1745
e
in
acquired resistance
to
cisplatin. Cancer Res
90.
226. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to
cisplatin in cells that have lost DNA mismatch repair. Cancer Res
1997;
57
:1841
1996;
56
:3087
e
25.
208. Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and
predictive relevance of microsatellite instability in colorectal
cancer. Oncol Rep 2005;
14
:241
e
5.
227. Lin X, Howell SB. Effect of loss of DNA mismatch repair on
development of topotecan-, gemcitabine-, and paclitaxel-resistant
variants after exposure to cisplatin. Mol Pharmacol 1999;
56
:390
e
9.
209. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and
colorectal cancer prognosis. Clin Cancer Res 2005;
11
:8332
5.
228. Strathdee G, MacKean MJ, Illand M, Brown R. A role for meth-
ylation of the hMLH1 promoter in loss of hMLH1 expression and
drug resistance in ovarian cancer. Oncogene 1999;
18
:2335
e
e
40.
210. Popat S, Hubner R, Houlston RS. Systematic review of micro-
satellite instability and colorectal cancer prognosis. J Clin Oncol
2005;
23
:609
e
41.
229. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the
role of DNA repair pathways. Clin Cancer Res 2008;
14
:1291
e
18.
211. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L.
Immunohistochemical test for MLH1 and MSH2 expression
predicts clinical outcome in stage II and III colorectal cancer
patients. J Clin Oncol 2006;
24
:2359
5.
230. Ono Y, Nonomura N, Harada Y, et al. Loss of p73 induction in
a
e
e
cisplatin-resistant bladder
cancer
cell
line. Mol Urol
30.
231. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of
dominant-negative p73 isoforms for responsiveness to chemo-
therapy and survival in ovarian cancer: evidence for a crucial
p53-p73 cross-talk in vivo. Clin Cancer Res 2005;
11
:8372
2001;
5
:25
e
67.
212. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and
predictive roles of high-degree microsatellite instability in colon
cancer: a National Cancer Institute-National Surgical Adjuvant
Breast and Bowel Project Collaborative Study.
e
83.
232. Corde S, Balosso J, Elleaume H, et al. Synchrotron photo-
activation of cisplatin elicits an extra number of DNA breaks that
stimulate RAD51-mediated repair pathways. Cancer Res
2003;
63
:3221
e
J Clin Oncol
72.
213. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF,
Uzzan B. Does microsatellite instability predict the efficacy of
2007;
25
:767
e
e
7.
